Loading...
Aclaris Therapeutics, Inc.
ACRS•NASDAQ
Healthcare
Medical - Diagnostics & Research
$1.70
$0.02(1.19%)
Aclaris Therapeutics, Inc. (ACRS) Financial Performance & Income Statement Overview
Review Aclaris Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-40.09%
↓ 40.09%
Operating Income Growth
-45.79%
↓ 45.79%
Net Income Growth
-49.26%
↓ 49.26%
Operating Cash Flow Growth
74.37%
↑ 74.37%
Operating Margin
-791.90%
↓ 791.90%
Gross Margin
20.55%
↑ 20.55%
Net Profit Margin
-732.42%
↓ 732.42%
ROE
-92.41%
↓ 92.41%
ROIC
-79.73%
↓ 79.73%
Aclaris Therapeutics, Inc. (ACRS) Income Statement & Financial Overview
Review Aclaris Therapeutics, Inc.'s (ACRS) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $9.21M | $4.35M | $2.77M | $2.40M |
| Cost of Revenue | -$3.37M | $2.41M | $1.91M | $1.84M |
| Gross Profit | $12.57M | $1.94M | $857000.00 | $558000.00 |
| Gross Profit Ratio | $1.37 | $0.45 | $0.31 | $0.23 |
| R&D Expenses | $9.03M | $5.96M | $8.76M | $9.85M |
| SG&A Expenses | $7.55M | $5.65M | $4.65M | $4.34M |
| Operating Expenses | $117.85M | $12.41M | $13.41M | $14.19M |
| Total Costs & Expenses | $114.49M | $14.82M | $15.32M | $16.03M |
| Interest Income | $5.96M | $1.99M | $0.00 | $0.00 |
| Interest Expense | $7.95M | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | -$622000.00 | $179000.00 | $200000.00 | $243000.00 |
| EBITDA | -$103.84M | -$9.49M | -$12.61M | -$15.99M |
| EBITDA Ratio | -$11.27 | -$2.18 | -$4.47 | -$5.58 |
| Operating Income | -$105.28M | -$10.47M | -$12.55M | -$13.63M |
| Operating Income Ratio | -$11.43 | -$2.41 | -$4.54 | -$5.68 |
| Other Income/Expenses (Net) | $8.72M | $2.88M | $1.87M | -$3.31M |
| Income Before Tax | -$96.55M | -$7.59M | -$10.99M | -$16.94M |
| Income Before Tax Ratio | -$10.48 | -$1.75 | -$3.97 | -$7.06 |
| Income Tax Expense | -$199724.00 | $0.00 | $0.00 | $199724.00 |
| Net Income | -$96.55M | -$7.59M | -$10.99M | -$16.94M |
| Net Income Ratio | -$10.48 | -$1.75 | -$3.97 | -$7.06 |
| EPS | -$1.25 | -$0.11 | -$0.15 | -$0.24 |
| Diluted EPS | -$1.25 | -$0.11 | -$0.15 | -$0.24 |
| Weighted Avg Shares Outstanding | $77.30M | $71.38M | $71.29M | $71.07M |
| Weighted Avg Shares Outstanding (Diluted) | $77.30M | $71.38M | $71.29M | $71.07M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan